Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders

Author:

Takai Yoshiki1,Misu Tatsuro1,Suzuki Hiroyoshi2,Takahashi Toshiyuki13,Okada Hiromi4,Tanaka Shinya5,Okita Kenji6,Sasou Shunichi7,Watanabe Mika8,Namatame Chihiro1,Matsumoto Yuki1,Ono Hirohiko1,Kaneko Kimihiko19,Nishiyama Shuhei1,Kuroda Hiroshi110,Nakashima Ichiro11,Lassmann Hans12,Fujihara Kazuo113,Itoyama Yasuto14,Aoki Masashi1

Affiliation:

1. Department of Neurology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

2. Department of Pathology, National Hospital Organization Sendai Medical Center, Sendai 983-8520, Japan

3. Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa 992-1202, Japan

4. Department of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan

5. Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo 060-0808, Japan

6. Department of neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan

7. Department of Pathology, Japanese Red Cross Society Hachinohe Hospital, Hachinohe 039-1104, Japan

8. Department of Pathology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

9. Department of Neurology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki 986-8522, Japan

10. Department of Neurology, South Miyagi Medical Center, Shibata 989-1253, Japan

11. Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan

12. Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna A-1090, Austria

13. Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima 960-1295, Japan

14. International University of Health and Welfare, Fukuoka 814-0001, Japan

Abstract

Abstract Aquaporin 4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD) is an autoimmune astrocytopathic disease pathologically characterized by the massive destruction and regeneration of astrocytes with diverse types of tissue injury with or without complement deposition. However, it is unknown whether this diversity is derived from differences in pathological processes or temporal changes. Furthermore, unlike for the demyelinating lesions in multiple sclerosis, there has been no staging of astrocytopathy in AQP4-IgG+NMOSD based on astrocyte morphology. Therefore, we classified astrocytopathy of the disease by comparing the characteristic features, such as AQP4 loss, inflammatory cell infiltration, complement deposition and demyelination activity, with the clinical phase. We performed histopathological analyses in eight autopsied cases of AQP4-IgG+NMOSD. Cases comprised six females and two males, with a median age of 56.5 years (range, 46–71 years) and a median disease duration of 62.5 months (range, 0.6–252 months). Astrocytopathy in AQP4-IgG+NMOSD was classified into the following four stages defined by the astrocyte morphology and immunoreactivity for GFAP: (i) astrocyte lysis: extensive loss of astrocytes with fragmented and/or dust-like particles; (ii) progenitor recruitment: loss of astrocytes except small nucleated cells with GFAP-positive fibre-forming foot processes; (iii) protoplasmic gliosis: presence of star-shaped astrocytes with abundant GFAP-reactive cytoplasm; and (iv) fibrous gliosis: lesions composed of densely packed mature astrocytes. The astrocyte lysis and progenitor recruitment stages dominated in clinically acute cases (within 2 months after the last recurrence). Findings common to both stages were the loss of AQP4, a decreased number of oligodendrocytes, the selective loss of myelin-associated glycoprotein and active demyelination with phagocytic macrophages. The infiltration of polymorphonuclear cells and T cells (CD4-dominant) and the deposition of activated complement (C9neo), which reflects the membrane attack complex, a hallmark of acute NMOSD lesions, were selectively observed in the astrocyte lysis stage (98.4% in astrocyte lysis, 1.6% in progenitor recruitment, and 0% in protoplasmic gliosis and fibrous gliosis). Although most of the protoplasmic gliosis and fibrous gliosis lesions were accompanied by inactive demyelinated lesions with a low amount of inflammatory cell infiltration, the deposition of complement degradation product (C3d) was observed in all four stages, even in fibrous gliosis lesions, suggesting the past or chronic occurrence of complement activation, which is a useful finding to distinguish chronic lesions in NMOSD from those in multiple sclerosis. Our staging of astrocytopathy is expected to be useful for understanding the unique temporal pathology of AQP4-IgG+NMOSD.

Funder

KAKENHI

Ministry of Education, Culture, Sports, Science and Technology

Japan and Grants-in-Aid for Scientific Research

Ministry of Health, Labour and Welfare of Japan

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3